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Abstract
Background: The Ras-assocation family (RASSF) of tumour suppressor genes (TSGs) contains 10
members that encode proteins containing Ras-assocation (RA) domains. Several members of the
RASSF family are frequently epigenetically inactivated in cancer, however, their role in leukaemia
has remained largely uninvestigated. Also, RASSF10 is a predicted gene yet to be experimentally
verified. Here we cloned, characterised and demonstrated expression of RASSF10 in normal human
bone marrow. We also determined the methylation status of CpG islands associated with RASSF1–
10 in a series of childhood acute lymphocytic leukaemias (ALL) and normal blood and bone marrow
samples.
Results: COBRA and bisulphite sequencing revealed RASSF6 and RASSF10 were the only RASSF
members with a high frequency of leukaemia-specific methylation. RASSF6 was methylated in 94%
(48/51) B-ALL and 41% (12/29) T-ALL, whilst RASSF10 was methylated in 16% (8/51) B-ALL and
88% (23/26) T-ALL. RASSF6 and RASSF10 expression inversely correlated with methylation which
was restored by treatment with 5-aza-2'deoxycytidine (5azaDC).
Conclusion: This study shows the hypermethylation profile of RASSF genes in leukaemias is
distinct from that of solid tumours and represents the first report of inactivation of RASSF6 or
RASSF10 in cancer. These data show epigenetic inactivation of the candidate TSGs RASSF6 and
RASSF10 is an extremely frequent event in the pathogenesis of childhood leukaemia. This study also
warrants further investigation of the newly identified RASSF member RASSF10 and its potential role
in leukaemia.
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Background
Mutation of the Ras superfamily of proteins, or of
upstream and downstream signalling components, plays
a significant role in the pathogenesis of most forms of can-
cer. Ras proteins interact with a wide variety of down-
stream effectors to regulate several signalling pathways
important for normal cellular growth [1]. However, Ras
proteins can also regulate apoptosis via several recently
described effectors, namely the RASSF family of tumour
suppressor proteins. The RASSF family consists of six 'clas-
sical' members, RASSF1–6, that contain C-terminal RA (of
the RalGDS/AF-6 variety) and Sav/RASSF/Hippo
(SARAH) protein interaction domains. Previously we and
others had demonstrated that several RASSF members,
namely RASSF1A, RASSF2, RASSF4 and RASSF5A are fre-
quently epigenetically inactivated by promoter region
CpG island hypermethylation in a broad range of solid
tumour types [2,3]. These proteins can regulate apoptosis
through several downstream effectors such as the mam-
malian Serine/Threonine kinases MST1 and MST2 and
modulator of apoptosis-1 (MOAP-1) [4-9]. Very recently
several additional RA domain-containing family mem-
bers have been identified and designated RASSF7 (also
known as HRC1 located 11p15.5), RASSF8 (also known
as HOJ-1 or C12ORF2 located 12p12.1), RASSF9 (also
known as P-CIP1  or  PAMCI  located 12q21.31) and
RASSF10 (also known as LOC644943 located 11p15.2).
These genes encode proteins that are divergent and struc-
turally distinct from RASSF1–6 and contain an RA domain
within their extreme N-termini but lack the SARAH
domain. Accordingly, RASSF7–10 are referred to as the 'N-
terminal' RASSF family to distinguish them from the 'clas-
sical' members RASSF1–6. RASSF7–10 represent an evolu-
tionarily conserved group of proteins with orthologues of
all four in the lower vertebrate Xenopus laevis and a
RASSF7/8 homologue [GenBank:CG5053], a RASSF9
homologue [GenBank:CG13875] and a RASSF10 homo-
logue [GenBank:CG32150] in Drosophila melanogaster dis-
tinct from the RASSF1–6 Drosophila  homologue
[GenBank:CG4656-PA] [10].
To date the role of the RASSF family in childhood leukae-
mia has remained uninvestigated and inactivation of the
'N-terminal' RASSF members has not been investigated in
any cancer. In this report we describe investigation of the
RASSF family for inactivation by promoter CpG island
hypermethylation in a large series of childhood B- and T-
ALL and find very frequent promoter hypermethylation
and loss of expression of RASSF6 and RASSF10 in B-ALL
and T-ALL respectively. These findings support the candi-
dacy of RASSF6 and RASSF10 as TSGs involved in the
pathogenesis of childhood leukaemias.
Results
Inactivation of RASSF6 in childhood leukaemia
We investigated the CpG island methylation status of the
'classical' RASSF members, RASSF1–6, in a large series of
childhood ALL to ascertain whether epigenetic inactiva-
tion of these genes occurs in childhood leukaemia. Sur-
prisingly, we found that RASSF1–5  were infrequently
methylated whilst RASSF6  was methylated in B-ALL
(94%; 48/51), T-ALL (41%; 12/29) and 5/5 unclassified
childhood leukaemias but not in normal blood or bone
marrow control samples (0/8 and 0/1 respectively; figure
1A, B, table 1 and Additional file 1; figure S1–2). Given
that  RASSF6  epigenetic inactivation has not previously
been observed in any cancer we next sought to determine
the extent of methylation across the RASSF6 CpG island
and determine whether methylation correlated with loss
or downregulation of RASSF6  expression. Bisulphite
sequencing of up to 12 individual alleles from 9 leukae-
mia cell lines, 6 B-ALL, 6 T-ALL, 1 pre-B-ALL, 6 normal
blood and 1 normal bone marrow sample confirmed leu-
kaemia-specific methylation across the entire RASSF6
CpG island in cell lines, B-ALL and T-ALL (figure 1C, and
Additional file 1; figure S3 and Additional file 2; table S1).
Whilst RT-PCR showed RASSF6 was expressed in all nor-
mal tissues analysed including bone marrow (see Addi-
tional file 1; figure S4A), and in the unmethylated
leukaemia cell line U937 (figure 1D and Additional file 1;
figure S4B), we observed absent or downregulated expres-
sion of RASSF6 in methylated leukaemia cell lines. Treat-
ment of hypermethylated leukaemia cell lines with
5azaDC and TSA (Trichostatin A) reactivated RASSF6
expression (figure 1D and Additional file 1; figure S4B).
Using a commercially available antibody that recognises
human RASSF6 protein we also observed restoration of
RASSF6 protein expression following 5azaDC and TSA
Table 1: A summary of RASSF6 and RASSF10 promoter 
methylation in leukaemia and control samples.
TISSUE/TUMOUR TYPE RASSF6 RASSF10
Leukaemia cell lines 10/11(91%) 7/7(100%)
Childhood B-ALL 48/51(94%) 8/51(16%)
Childhood T-ALL 12/29(41%) 23/26(88%)
Childhood Pre-B-ALL 0/1 0/1
Unclassified Childhood Leukaemia 5/5 0/5
Normal Blood 0/8 0/21
Normal Bone Marrow 0/1 0/1Molecular Cancer 2009, 8:42 http://www.molecular-cancer.com/content/8/1/42
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RASSF6 is hypermethylated in childhood leukaemias Figure 1
RASSF6 is hypermethylated in childhood leukaemias. A, COBRA analysis showing methylation of RASSF6 in leukaemia 
cell lines. No methylation was observed in normal blood or bone marrow (BM). The methylation index (MI) for each is shown 
below the gel image. U = undigested PCR product; T = TaqI digested PCR product. B, COBRA analysis of B-ALL and T-ALL 
childhood leukaemias. C, Cloning and bisulphite sequencing of the RASSF6 CpG island. Top left shows a schematic of the region 
analysed relative to the RASSF6 gene. Exon 1 of RASSF6A [GenBank:NM_177532] and RASSF6B [GenBank:NM_201431] is 
shown relative to the CpG island region (hatched bar), the region amplified by COBRA PCR (black bar) and the location of 
COBRA primers (F, FN and R). The remaining 5 panels show representative data from primary B-ALL and T-ALL leukaemias 
27 and 6 respectively with leukaemia cell lines CEM, U937 and THP-1. Each horizontal line represents an individual allele whilst 
the circles represent single CpG dinucleotides. Filled circle represents a methylated CpG dinucleotide whereas an open circle 
represents an unmethylated CpG dinucleotide. Indicated by the arrow is the transcription start site of RASSF6A. The dashed 
vertical line indicates the CpG dinucleotide within the TaqI restriction site (TCGA) used to assay for methylation. D, Methyla-
tion of the RASSF6 CpG island correlates with loss or downregulation of RASSF6 expression. Methylated cell lines CEM, THP-1 
and the unmethylated cell line U937 were cultured in the presence or absence of 5azaDC and TSA. RT-PCR analysis showed 
loss or downregulation of RASSF6 expression correlates with the methylation status of the RASSF6 CpG island (A and C). 
RASSF6 expression is restored following 5azaDC and TSA treatment. GAPDH was used as a control for RNA integrity and equal 
loading. E, RASSF6 protein expression is lost or downregulated in methylated leukaemia cell lines. We used an antibody 
towards human RASSF6 protein to investigate expression before and after 5azaDC and TSA treatment. a-Tubulin was used as 
a control for equal loading.
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treatment in protein lysates from leukaemia lines (figure
1E). Thus methylation of the RASSF6 CpG island results
in loss of RASSF6 expression. As mentioned previously,
several RASSF members have been shown to bind Ras pro-
teins, including RASSF6 [11]. Previously we had also dem-
onstrated that inactivation of RASSF2  by promoter
hypermethylation inversely correlates with K-Ras muta-
tion status in colorectal carcinomas [12]. We investigated
our series of leukaemias for mutations to codons 12, 13
and 61 of both K- and N-Ras. K-Ras mutations were found
in 2.2% (2/89) whilst N-Ras mutations were found in
11.2% (10/89) leukaemias. However, no association was
found between Ras mutation status and RASSF6 methyla-
tion status.
Characterisation of the human RASSF10 gene
The human RASSF10 gene has been predicted based on
homology with RASSF9/P-CIP1  but has yet to be sup-
ported by experimental evidence. UCSC http://
www.genome.ucsc.edu and Ensembl http://
www.ensembl.org human genome browsers predict a 615
amino acid protein encoded by a two exon gene separated
by a short intron of 104 bp. Interestingly, no 5' or 3'UTRs
were predicted, hence we reasoned RASSF10 had not been
completely characterised. Sequencing of the only IMAGE
clone available [IMAGE:4413366] [GenBank:BG034782]
obtained from a human liver cDNA library revealed a
3'UTR of 478 bp beyond the predicted stop codon fol-
lowed by a poly A-tail. Contrary to the UCSC and
Ensembl genome browsers however, the IMAGE clone
sequence suggested the RASSF10  gene did not contain
introns and predicted alternative transcription and trans-
lation initiation sites located Chr11:12,987,466 and
Chr11:12,987,700 respectively (UCSC genome browser,
March 2006 freeze). Analysis of the sequence flanking this
alternative ATG (GCCATGG) support its candidacy as a
genuine translation initiation site since it matches the
consensus 'Kozak' sequence of A/GCCATGG in which the
important -3 and +4 A/G and G residues respectively
(underlined) were conserved [13,14]. Furthermore, trans-
lation initiation site prediction software at http://dnafs
miner.bic.nus.edu.sg also predicted the ATG at
Chr11:12,987,700 is the translation initiation site within
the RASSF10 gene. This suggested the RASSF10 gene con-
tains a shorter open reading frame encoding a 507 amino
acid protein. However, since the IMAGE clone may be
incomplete we confirmed the transcription start site of the
RASSF10  gene using 5'RACE. We first demonstrated
expression of the RASSF10  transcript in DNaseI-treated
normal human bone marrow RNA using RT-PCR (figure
2A). This RNA was then subjected to 5'RACE using
RASSF10-specific antisense primers, which generated a
major product of ~330 bp and several larger and smaller
minor products (figure 2B). These products were gel puri-
fied, cloned and sequenced to reveal a transcription start
site located at Chr11:12,987,444 (UCSC genome browser,
March 2006 freeze) with two alternative transcription
start sites at +119 bp and +169 bp (Chr11:12,987,565 and
Chr11:12,987,613, respectively). This revealed the pres-
ence of a 5'UTR of up to 431 bp and confirms the
RASSF10 gene likely encodes a much shorter 507 amino
acid protein. That the predicted N-terminal 108 amino
acids may not actually be part of the RASSF10 protein is
supported by ClustalW alignments of RASSF7–10. These
alignments show the predicted N-terminal 108 amino
acids are extremely divergent with no significant homol-
ogy to RASSF7–9 or with any other human protein (figure
2C and 2D). Interestingly, the Rassf10 murine protein
[Genbank:NP_780488] also lacks this divergent N-termi-
nus and is 508 amino acids in length. Therefore, we have
characterised the human RASSF10  gene and verified
expression in normal bone marrow. We provide evidence
that RASSF10 is a single exon gene with a 5'UTR of up to
431 bp, a 3'UTR of 478 bp and an open reading frame
encoding a protein of 507 amino acids, not 615 amino
acids as predicted by current versions of human genome
browsers.
Inactivation of RASSF10 in childhood leukaemia
RASSF10  contains a large CpG island that covers the
majority of the gene. Given the expression of RASSF10 in
bone marrow we questioned whether RASSF10  is also
inactivated by promoter methylation in the same series of
childhood leukaemias. We investigated the RASSF10 CpG
island for DNA hypermethylation using COBRA and
bisulphite sequencing. The RASSF10  CpG island was
heavily methylated in 7/7 leukaemia cell lines (figure 3A).
Next, we investigated childhood B- and T-ALL, normal
blood and normal bone marrow for evidence of RASSF10
CpG island hypermethylation. We found RASSF10 was
methylated in 23/26 (88%) T-ALL and 8/51 (16%) B-ALL
but was unmethylated in normal bone marrow and 21
normal blood samples (figure 3A, table 1). Direct bisul-
phite sequencing of the RASSF10 CpG island confirmed
the presence of dense methylation across the entire region
analysed (figure 3B). To investigate the effects of methyl-
ation on RASSF10 expression we analysed the leukaemia
cell lines THP-1 and SUP-T1 using RT-PCR. We found low
level expression of RASSF10 in THP-1 (partially methyl-
ated) and loss of RASSF10 expression in SUP-T1 (com-
pletely methylated) and in both cases expression was
upregulated following 5azaDC and TSA treatment (figure
3C). Thus, methylation of the RASSF10 CpG island inac-
tivates expression of the gene very frequently in T-ALL and
in a subset of B-ALL.
Next, we investigated the remaining 'N-terminal' RASSF
members to determine whether they too become inacti-
vated in childhood leukaemias. RASSF7 and RASSF8 both
contain 5' CpG islands encompassing their first exon,Molecular Cancer 2009, 8:42 http://www.molecular-cancer.com/content/8/1/42
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whilst RASSF9 does not contain a CpG island. As deter-
mined by COBRA and bisulphite sequencing, RASSF7 was
unmethylated in all leukaemia cell lines analysed (0/5).
RASSF8 methylation was found to be infrequent, occur-
ring in 2/6 leukaemia cell lines, 2/19 (10%) childhood T-
ALLs, and 4/46 (9%) B-ALL with no methylation detecta-
ble in normal bone marrow or normal blood (0/7). Meth-
ylation of the RASSF8 CpG island correlated with loss of
RASSF8 expression which was restored following treat-
ment with 5azaDC (and Additional file 1; figure S5).
Discussion
In recent years several members of the classical RASSF
family have emerged as important TSGs [2,3,15]. Whether
inactivation of RASSF1-6 plays a role in leukaemia has not
yet been determined. We found that RASSF1-5 were not
frequently methylated in our series of childhood ALL.
Instead, we observed very frequent inactivation of RASSF6
reiterating the importance of several classical RASSF mem-
bers in the development of different forms of cancer. Evi-
dence is accumulating that RASSF6  plays a role in
tumourigenesis and likely functions as a regulator of
apoptosis [2]. RASSF6 is downregulated in 30–60% of a
variety of solid tumours [11]. SiRNA-mediated knock-
down of RASSF6 enhances tumourigenic growth in soft
agar whilst RASSF6  overexpression reduces tumour
growth in a variety of tumour cell lines [11,16]. The
growth inhibitory properties of RASSF6 are most likely a
result of induction of apoptosis since RASSF6-induced cell
death was concomitant with a variety of apoptotic mark-
Characterisation of the RASSF10 gene Figure 2
Characterisation of the RASSF10 gene. A, RT-PCR analysis showing expression of RASSF10 in normal human bone mar-
row. B, The 5' region of the RASSF10 transcript was amplified from normal human bone marrow using 5'RACE. Arrowed is the 
major product of 5'RACE which was cloned and sequenced to determine the transcription start point and open reading frame 
of the RASSF10 gene. C, Schematic summarising the structure of the RASSF10 gene and the open reading frame encoding a 
shortened protein of 507amino acids that does not contain the in silico predicted N-terminal 108 amino acids that are divergent 
from the RASSF7–9 proteins. D, ClustalW alignments of RASSF7–10 proteins including both the in silico predicted 615 amino 
acid RASSF10 [GenBank:NM_001080521] and the shorter 507 amino acid RASSF10 confirmed in this study suggesting the 
divergent N-terminal 108 amino acids is not likely to be part of the RASSF10 protein.
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ers [11,16]. Previously, we had demonstrated that RASSF6
interacted with K-Ras in a GTP-dependent manner and
that RASSF6-induced apoptosis was enhanced synergisti-
cally by co-transfection with constitutively active K-
RasG12V [11]. Thus, RASSF6  can mediate the growth
inhibitory properties of Ras proteins. In agreement with
previous studies [17-19] the frequency of mutations to
codons 12, 13 and 61 of both K- and N-Ras combined in
our series of leukaemias was only 14% (12/89). Therefore,
inactivation of RASSF6 may provide the alternative mech-
anism of Ras pathway inactivation in B-ALL. In T-ALL, in
which  RASSF6  methylation is less frequent, RASSF1A,
RASSF5A and RASSF6 methylation may account for Ras
pathway inactivation in the majority of cases.
The recently identified 'N-terminal' RASSFs consist of four
members designated RASSF7–10 [20]. RASSF7–10 repre-
sents a structurally distinct yet evolutionarily conserved
RASSF10 is hypermethylated in childhood leukaemias Figure 3
RASSF10 is hypermethylated in childhood leukaemias. A, COBRA analysis showing methylation status of RASSF10 in 
leukaemia cell lines and normal bone marrow, normal blood, primary T-ALL and primary B-ALL. No methylation was observed 
in normal blood or bone marrow (BM). U = undigested PCR product; T = TaqI digested PCR product. B = BstUI digested PCR 
product. B, Direct bisulphite sequencing of normal blood, normal bone marrow, leukaemia cell lines and primary T-ALL leu-
kaemias. Top shows a schematic of the region amplified by COBRA PCR (black bar) relative to the RASSF10 gene and CpG 
island region (hatched bar). Each horizontal line represents the total DNA amplified from the sample whilst the circles repre-
sent single CpG dinucleotides. Filled black circle represents a completely methylated CpG dinucleotide, open circle represents 
a completely unmethylated CpG dinucleotide and filled gray circle represents a partially methylated CpG dinucleotide. The 
dashed vertical line indicates the CpG dinucleotides within TaqI (TCGA) and BstUI (CGCG) restriction sites used to assay for 
methylation. C, Methylation of the RASSF10 CpG island correlates with loss or downregulation of RASSF10 expression. The 
partially methylated cell line THP-1 and the completely methylated cell line SUP-T1 were cultured in the presence or absence 
of 5azaDC and TSA. RT-PCR analysis showed loss or downregulation of RASSF10 expression correlates with the methylation 
status of the RASSF10 CpG island (A and B). RASSF10 expression is restored following 5azaDC and TSA treatment. GAPDH was 
used as a control for RNA integrity and equal loading. Ct = control mock treated; RT = reverse transcriptase.
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sub-group of the RASSF family. It has not yet been deter-
mined whether RASSF7–10 bind to Ras proteins. We
found no evidence of methylation of RASSF7 in leukae-
mia cell lines. Hypermethylation of the RASSF8  CpG
island and loss of RASSF8 expression was observed in 2/6
leukaemia cell lines.
However, since we observed RASSF8 CpG island hyper-
methylation in only 2/19 T-ALLs and 4/46 B-ALLs we sus-
pect inactivation of RASSF8  may be involved in the
pathogenesis of only a small subset of leukaemias.
RASSF9  was not investigated for inactivation by DNA
methylation due to lack of a CpG island.
LOC644943 was very recently designated RASSF10 based
on its homology with RASSF9/P-CIP1. The existence of
this gene in humans has yet to be experimentally verified.
However, the Drosophila  homologue,  CG32150, is
expressed in several sensory organ precursors and seems
to be required for correct Hedgehog pathway signaling
[21,22]. Orthologues of human RASSF10 can be found in
several model species including X.laevis  [Gen-
Bank:NM_001115020] and M.musculus  [Gen-
Bank:NM_175279]. Murine Rassf10 is expressed in several
tissues including salivary gland, testes, kidney, lung and
brain. X.laevis and M.musculus Rassf10 proteins share 60
and 85% identity with human RASSF10 respectively. To
date there has been no investigation of vertebrate
RASSF10. Here we characterized the human RASSF10
gene and transcript and demonstrate expression in nor-
mal human bone marrow. Whether RASSF10 is expressed
in other tissues was not determined in the present study,
though this is likely since we obtained an IMAGE clone
derived from a normal human liver cDNA library. Further-
more, in silico sources (Unigene [Hs.693473] and Gene-
cards) provide further evidence of expression in brain,
skeletal muscle, pancreas, liver and trachea. Interestingly,
we demonstrate that current genome browser predictions
of the RASSF10 gene and protein may require revision and
provide evidence of alternative transcription and transla-
tion inititation sites that produce a much shorter protein
of 507 amino acids. We also found RASSF10 was very fre-
quently inactivated in T-ALL (88%). RASSF10 CpG island
methylation correlated with loss of RASSF10 expression
which was restored following 5azaDC and TSA treatment.
It is particularly interesting that RASSF6  methylation
occurs very frequently in B-ALL whilst RASSF10 methyla-
tion is more restricted to T-ALL. It is unclear at present
whether this represents independent routes to inactiva-
tion of the same pathway or whether it reflects inactiva-
tion of separate pathways important in the development
of these different subtypes of leukaemia. Nevertheless,
inactivation of RASSF6  or RASSF10  by promoter DNA
hypermethylation appears to be an event associated with
the majority of childhood leukaemias.
Conclusion
In summary, we show that the hypermethylation profile
of RASSF genes in leukaemias is distinct from that of solid
tumours and show for the first time that RASSF6 is also
inactivated in cancer, but specifically in leukaemias. Given
the emerging role of RASSF6 as a Ras effector and possible
TSG involved in the regulation of apoptosis it is likely that
loss of expression may be involved in the ability of leukae-
mic cells to evade apoptosis. Our data also suggests that of
the newly identified 'N-terminal' RASSF genes, RASSF10 is
an interesting candidate for further analysis in other types
of cancer and for functional investigation to ascertain its
role in leukaemias.
Methods
Tumour samples
Twelve leukaemia cell lines (DND-41, CCRF-CEM (CEM),
U937, Jurkat (JKT), TALL-1, NALM1, NALM6, NALM16,
NALM17, THP-1, SUP-T1 and MOLT-4) and 89 primary
childhood ALL comprising 51 B-cell ALL (B-ALL), 32 T-
cell ALL (T-ALL), 1 pre-B-ALL and 5 unclassified leukae-
mias were analysed. In addition a total of 21 normal
blood samples and 1 normal bone marrow (BM, AMS Bio-
technology) sample were used as controls. All DNA sam-
ples were obtained with informed consent from patients
and family members.
Methylation analysis
Bisulphite modification was performed as described pre-
viously [23]. Promoter methylation status of RASSF1A
and RASSF2 were determined using MSP as described pre-
viously [12]. The methylation status of RASSF3, RASSF4
and RASSF5A were determined by combined bisulphite
restriction analysis (COBRA) as described in Hesson et al.,
[12], Hesson et al., [23] and Eckfeld et al., [24]. For
RASSF6, primers were designed to amplify the entire CpG
island encompassing the first exons of RASSF6A
(NM_177532) and RASSF6B (NM_201431) from bisul-
phite modified DNA using semi-nested bisulphite PCR
(see additional file 2; table S2 for primer sequences). The
methylation status of RASSF7, RASSF8 and RASSF10 were
determined by COBRA and direct bisulphite sequencing.
For RASSF7 and RASSF8 primers were designed to amplify
a portion of the CpG island encompassing exon 1. The
RASSF10 CpG island covers the majority of the gene. We
designed primers to amplify a portion of the CpG island
encompassing the 5' region of the gene. Five microlitres of
PCR product was incubated with 2 U TaqI  restriction
enzyme (TCGA) for 2 h at 65°C or 2 U BstUI restriction
enzyme (CGCG) for 2 h at 60°C before visualisation on a
2% agarose gel. Samples selected for bisulphite sequenc-
ing were cloned (RASSF6) into the CloneJET vector (Fer-
mentas) according to manufacturers instructions or
sequenced directly (RASSF8 and RASSF10). Up to 12 indi-
vidual colonies were chosen for colony PCR using theMolecular Cancer 2009, 8:42 http://www.molecular-cancer.com/content/8/1/42
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RASSF6 COBRA primers. Products were then sequenced
to ascertain the methylation status of individual alleles
and to determine the methylation index (MI). The MI was
calculated as a percentage using the equation; number of
CpG dinucleotides methylated/total number of CpG
dinucleotides sequenced × 100.
Cell lines, 5azaDC treatment and RT-PCR
Leukaemia cell lines were maintained in RPMI1640
(Sigma) supplemented with 10% FCS, 2 mM Glutamine,
20 mM HEPES, 1 mM Sodium Pyruvate and 12.6 mM
Glucose Monohydrate at 37°C, 5% CO2. Cells were
treated with 5 mM of the DNA demethylating agent
5azaDC (Sigma) freshly prepared in ddH2O and filter-
sterilised. The medium (including 5 mM 5azaDC) was
changed every day for 5 days. Cells were also treated on
day 4 with 0.1 mM TSA for 24 hrs. RNA was prepared using
RNA bee (AMS biotechnology) according to manufactur-
ers' instructions. cDNA was generated from 1 mg total RNA
using SuperScript III (Invitrogen) and polyN primers. We
analysed expression of RASSF6 using primers specific for
exons 2 and 4 that amplify both the A and B isoforms (F
= 5'-ATGATGGCTCACCAGTACCC-3' and R = 5'-GGT
CGTTTTACTCCCCAGAA-3'). We analysed expression of
RASSF10  using the primers 5'-CCATGACCCAGGA-
GAAACAG-3' (F) and 5'-TGCTGGCGAATTGTGTGGTC-3'
(R). Since RASSF10 is a single exon gene we first DNaseI
(Fermentas) treated all RNA samples prior to cDNA syn-
thesis and included control experiments in which reverse
transcriptase was omitted (No RT controls) in all samples
analysed. We analysed expression of RASSF8 using the
primers F = 5'-TCCATTGAGAAACAGCTGGA-3' and R =
5'-TGGCACAAATCAAAAAGGAA-3'. In all cases a GAPDH
control was included using conditions described previ-
ously [12]. RASSF6, RASSF8 and RASSF10 were amplified
from 50 ng cDNA using 0.8 mM of each primer, 3 mM
MgCl2, 0.25 mM dNTPs and 1 U Fast start Taq (Roche).
Protein expression
Leukaemia lines THP-1 and CEM were treated with
5azaDC as above. Protein extracts were then prepared by
lysis in 50 mM TrisHCl pH7.5, 1 mM EDTA, 1 mM EGTA,
50 mM Sodium Fluoride, 5 mM Sodium Pyrophosphate,
1 mM Sodium Orthovanadate, 0.27 M Sucrose, 1% Triton
and protease inhibitor cocktail (Roche). Twenty micro-
grams of protein extracts were resolved by SDS-PAGE,
transferred to PVDF membrane and probed for the pres-
ence of RASSF6 using 1 mg/mL anti-RASSF6 rabbit-raised
polyclonal antibody (ProteinTech Group).
5' Rapid Amplification of cDNA Ends (RACE)
One microgram of total RNA from bone marrow (AMS
Biotechnology) was DNaseI (Fermentas) treated accord-
ing to manufacturers instructions. We synthesised cDNA
using a 5'/3' RACE kit (2nd generation, Roche) and the
RASSF10  antisense primer 5'-TGCTGGCGAATTGTGT-
GGTC-3'. The 5' UTR of the RASSF10  transcript was
obtained using nested PCR with the nested antisense
RASSF10-specific primers 5'-GCTGTTTCTCCTGGGT-
CATG-3' and 5'-TATCTTCTTTTCCGAAGGATCCATG-3'
used in combination with a polyT-anchor primer. Control
experiments in which reverse transcriptase was omitted
were also performed to eliminate DNA contamination.
PCR products were gel extracted, sequenced and the
sequences obtained aligned against the human genome
browser.
Mutation analysis
PCR primers were used to amplify exons 2 and 3 of the K-
and N-Ras genes from genomic DNA. The primers were as
follows: K-Ras exon 2 F 5'-TTTGTATTAAAAGGTACTGGT-
GGAG-3'; K-Ras exon 2 R 5'-CCTTTATCTGTATCAAA-
GAATGGTC-3'; K-Ras exon 3 F 5'-CTGTGTTTCTCCCTTC
TCAGG-3'; K-Ras exon 3 R 5'-AGAAAGCCCTCCCCAGT
CCT-3'; N-Ras exon 2 F 5'-GATGTGGCTCGCCAATTAAC-
3'; N-Ras exon 2 R 5'-GAATATGGGTAAAGATGATCCG
AC-3'; N-Ras exon 3 F 5'-GTTAGATGCTTATTTAACCTT-
GGC-3'; N-Ras exon 3 R 5'-TGTGGTAACCTCATTTCCCC-
3'. PCR products were directly sequenced using ABI
BigDye cycle sequencing kit (Perkin-Elmer).
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Additional file 1
RASSF methylation profile. The data provided represent analysis of 
RASSF members and additional data relating to RASSF6 and RASSF10 
in childhood leukaemia. Figure S1: RASSF methylation profile of leu-
kaemia cell lines. The methylation status of RASSF1A and RASSF2 was 
determined using MSP whereas the methylation status of RASSF3-6 were 
determined using COBRA. RASSF1A, RASSF5A and RASSF6 were 
hypermethylated in leukaemia cell lines whereas RASSF2 and RASSF3 
showed no evidence of methylation. RASSF4 was methylated in both leu-
kaemia cell lines and normal blood. For MSP assays M = methylated spe-
cific PCR; U = unmethylated specific PCR. For COBRA assays U = 
undigested PCR product; T = TaqI digested PCR product. Figure S2: 
RASSF methylation profile of primary leukaemias. RASSF genes show-
ing evidence of hypermethylation in leukaemia cell lines were investigated 
for methylation in B-ALL and T-ALL leukaemias. RASSF1A and 
RASSF5A were infrequently methylated in T-ALL (2/12 and 2/24 respec-
tively). RASSF4 was methylated in 25/25 T-ALL but in only 7/50 B-ALL 
leukaemias, however given the low level methylation of RASSF4 observed 
in normal blood this gene was not investigated further. RASSF6 was meth-
ylated in 48/51 (94%) B-ALL and 12/29 (41%) T-ALL but not in nor-
mal bone marrow (BM) or blood control samples. For MSP assays M = 
methylated specific PCR; U = unmethylated specific PCR. For COBRA 
assays U = undigested PCR product; T = TaqI digested PCR product. Fig-
ure S3: Bisulphite sequencing of the RASSF6 CpG island. As in figure 
1C up to 12 alleles from B-ALL, T-ALL leukaemia cell lines, normal blood 
and normal bone marrow were cloned and sequenced. The methylation 
index (MI) is given for each. Figure S4: RASSF6 expression in normal 
tissues and leukaemia cell lines. A, RASSF6 mRNA was detected in all 
tissues analysed. B, Restoration of RASSF6 mRNA expression in methyl-
ated leukaemia cell lines following treatment with 5azaDC and TSA 
showing the additional cell lines JKT and REH. GAPDH was used as a 
control for equal loading. Figure S5: Methylation of the RASSF8 CpG 
island infrequently inactivates RASSF8 in leukaemias. A, Direct bisul-
phite sequencing of RASSF8 CpG island PCR products. Filled black circle 
represents a completely methylated CpG dinucleotide, open circle repre-
sents a completely unmethylated CpG dinucleotide and filled gray circle 
represents a partially methylated CpG dinucleotide. B, Methylation of the 
RASSF8 CpG island correlates with loss or downregulation of RASSF8 
expression which is restored following 5azaDC treatment.
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Additional file 2
RASSF6 methylation indexes and PCR primers used within this study. 
The data provided summarise RASSF6 methylation index data in cell 
lines, primary tumour and control samples (Table S1). PCR primers used 
in this study are also listed (Table S2). Table S1: A summary of the meth-
ylation index of the RASSF6 CpG island in leukaemia cell lines, B-ALL, 
T-ALL and normal blood and bone marrow control samples. Table S2: 
MSP and COBRA primer sequences used within this study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-42-S2.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2009, 8:42 http://www.molecular-cancer.com/content/8/1/42
Page 10 of 10
(page number not for citation purposes)
22. Nybakken K, Vokes SA, Lin TY, McMahon AP, Perrimon N: A
genome-wide RNA interference screen in Drosophila mela-
nogaster cells for new components of the Hh signaling path-
way.  Nat Genet 2005, 37:1323-1332.
23. Hesson L, Bieche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER,
Latif F: Frequent epigenetic inactivation of RASSF1A and
BLU genes located within the critical 3p21.3 region in glio-
mas.  Oncogene 2004, 23:2408-2419.
24. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ: RASSF4/
AD037 is a potential ras effector/tumor suppressor of the
RASSF family.  Cancer Res 2004, 64:8688-8693.